We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

1
Home
Companies

Synta Pharmaceuticals

Synta Pharmaceuticals
Leadership team

Keith R. Gollust (Independent Director)

James M. Daly (Independent Director)

Frederick B. Craves (Independent Lead Director)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
50 - 100
Headquarters
Lexington, Massachusetts, United States
Established
2000
Company Registration
SEC CIK number: 0001157601
Traded as
NASDAQ:SNTA
Social Media
URL
www.syntapharma.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Synta Pharmaceuticals is a pharmaceutical company that specializes in the development of drugs to improve patients' lives. Our mission is to discover, develop, and commercialize innovative therapeutic treatments for unmet medical needs. Through our commitment to innovation, research and development, we are able to provide effective solutions for our customers in fields such as oncology, inflammation & immunology, and metabolic & metabolic disorders.
History

Founded in 1995, Synta Pharmaceuticals is a research driven pharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs. We have the largest and most diverse pipeline of products in the field. We have successfully developed and commercialized products such as Synthiase, the first novel orally available protease inhibitor, which was approved by the FDA in 2001. We also developed the first inhalable insulin, Apidra, which was approved by the FDA in 2004. Since then, our research and development teams have been working diligently on several projects in the fields of oncology, inflammation/immunology, metabolic/metabolic disorders and skin diseases, to name a few.

Mission
Synta Pharmaceuticals’ mission is to discover, develop, and commercialize innovative, effective, cost-efficient therapeutic treatments for unmet medical needs, enhancing the lives of patients and their physicians.
Vision
Synta Pharmaceuticals strives to be an attractive partner for collaborations, to develop safe and effective new treatments for patients with unmet medical needs.
Key Team

Kenneth M. Bate (Independent Director)

Richard S. Levy (Independent Director)

Paul A. Friedman (Chairman & CEO)

David V. Milligan (Independent Director)

Rebecca A. Taub (Founder, Chief Medical Officer, President of Research & Development and Director)

Recognition and Awards
Synta Pharmaceuticals’ commitment to innovation, research and development has been recognized by some of the most distinguished organizations. We have received numerous awards from organizations such as the World Health Organization, Pharmaceutical Research and Manufacturers of America, the American Medical Association, and the National Institutes of Health for our contributions to their fields.
References

https://in.investing.com/equities/synta-pharmaceuticals

https://finance.yahoo.com/quote/SNTA/profile?p=SNTA

https://www.crunchbase.com/organization/synta-pharmaceuticals

www.syntapharma.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Synta Pharmaceuticals
Leadership team

Keith R. Gollust (Independent Director)

James M. Daly (Independent Director)

Frederick B. Craves (Independent Lead Director)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
50 - 100
Headquarters
Lexington, Massachusetts, United States
Established
2000
Company Registration
SEC CIK number: 0001157601
Traded as
NASDAQ:SNTA
Social Media
URL
www.syntapharma.com